NEW YORK, January 9, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting C.R. Bard, Inc. (NYSE: BCR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Seattle Genetics, Inc. (NASDAQ: SGEN), and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
C.R. Bard, Inc. Research Report
On January 6, 2014, C.R. Bard, Inc. (Bard) announced that it will host a conference call on January 30, 2014 at 5:00 p.m. EST to discuss the Company's operating results for Q4 2013 and full-year 2013 and to provide financial guidance for 2014. The Company stated that it will issue an earnings press release after the market closes on January 30, 2014. Bard added that a live audio webcast of the conference and its replay will be available through the Company's website. The Full Research Report on C.R. Bard, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/141e_BCR
--
Regeneron Pharmaceuticals Inc. Research Report
Regeneron Pharmaceuticals Inc. (Regeneron) posted on the Events page of the Company website that it will present at the 32nd Annual J.P. Morgan Healthcare Conference at Westin St. Francis Hotel, San Francisco, California on January 14, 2014 at 7:30 a.m. PT. According to the Company, a webcast of the presentation can be accessed via the Events and Presentations section of the Company website. The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/8ea7_REGN
--
Alexion Pharmaceuticals, Inc. Research Report
On January 6, 2014, Alexion Pharmaceuticals, Inc.'s (Alexion) stock declined 1.41%, ending the day at $129.86. Over the previous three trading sessions, shares of Alexion declined 2.27%, compared to the Nasdaq Composite which lost 1.51% during the same period. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/4619_ALXN
--
Seattle Genetics, Inc. Research Report
On January 6, 2014, Seattle Genetics, Inc. (Seattle Genetics) announced that its President and CEO, Clay B. Siegall, Ph.D., will present at the 32nd Annual J.P. Morgan Healthcare Conference on January 13, 2014 at 9:30 a.m. PT. The Company added that the presentation will be webcast live and available for replay through the Investors and News section of the Company website. The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/ff98_SGEN
--
Isis Pharmaceuticals, Inc. Research Report
On January 6, 2014, Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) announced that its management will present an overview of the Company at the 32nd Annual J.P. Morgan Healthcare Conference on January 13, 2014 at 4:30 p.m. PT in San Francisco, California. The Company said that a live audio webcast of the presentation can be accessed via the Investors & Media section of the Company website. Isis added that a replay of the conference will be available on its website within 48 hours and will be archived for a limited period. The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/fcfc_ISIS
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsCorner.com
SOURCE Analysts' Corner
